Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Even after the enactment of a patent law in 2000, pharmaceutical and biotech-related inventions are perceived to lack strong product patent protection in Pakistan.
For authorized biosimilars to achieve full acceptance in the marketplace, it is crucial that they are considered to be therapeutically equivalent and interchangeable with the brand reference product.
Accounting for errors arising from different high-throughput sequencing platforms and those arising from the approaches used to call variants are at the center of a controversy in RNA editing.